Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
To compare the efficacy and safety of gefitinib combined with bevacizumab and gefitinib in
the treatment of L858R positive mutation in exon 21 of EGFR gene in advanced NSCLC.